- MRK has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $691.9 million.
- MRK traded 40,379 shares today in the pre-market hours as of 7:48 AM.
- MRK is down 2% today from Friday's close.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in MRK with the Ticky from Trade-Ideas. See the FREE profile for MRK NOW at Trade-Ideas More details on MRK: Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. The stock currently has a dividend yield of 3.6%. MRK has a PE ratio of 28.5. Currently there are 7 analysts that rate Merck a buy, 1 analyst rates it a sell, and 6 rate it a hold. The average volume for Merck has been 11.9 million shares per day over the past 30 days. Merck has a market cap of $139.1 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.55 and a short float of 1.1% with 2.17 days to cover. Shares are up 16.1% year to date as of the close of trading on Friday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Highlights from the ratings report include:
- The current debt-to-equity ratio, 0.59, is low and is below the industry average, implying that there has been successful management of debt levels. Along with the favorable debt-to-equity ratio, the company maintains an adequate quick ratio of 1.41, which illustrates the ability to avoid short-term cash problems.
- The gross profit margin for MERCK & CO is currently very high, coming in at 79.48%. Regardless of MRK's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, MRK's net profit margin of 8.22% is significantly lower than the industry average.
- MERCK & CO's earnings per share declined by 48.3% in the most recent quarter compared to the same quarter a year ago. The company has suffered a declining pattern of earnings per share over the past year. However, we anticipate this trend reversing over the coming year. During the past fiscal year, MERCK & CO reported lower earnings of $2.00 versus $2.03 in the prior year. This year, the market expects an improvement in earnings ($3.47 versus $2.00).
- MRK, with its decline in revenue, underperformed when compared the industry average of 2.2%. Since the same quarter one year prior, revenues fell by 10.6%. Weakness in the company's revenue seems to have hurt the bottom line, decreasing earnings per share.
- Net operating cash flow has decreased to $2,338.00 million or 19.93% when compared to the same quarter last year. Despite a decrease in cash flow MERCK & CO is still fairing well by exceeding its industry average cash flow growth rate of -43.41%.
- You can view the full Merck Ratings Report.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.